Searchable abstracts of presentations at key conferences in obesity

ob0002cd1.4 | Case Discussions: Complex Clinical Cases 1 | OU2020

Liraglutide downregulates the expression of miRNA-424 in patients with obesity

Dimitriadis Georgios K , Dimitri Federica , Bate Danielle , Leca Bianca , Davasgaium Allan , Tripathi Gyanendra , Miras Alexander D , Rubino Francesco , Christian Mark , Randeva Harpal S

Aims: Liraglutide 3 mg once daily is an approved, prescription injectable Glucagon Like Peptide-1 receptor agonist that, when used with a low-calorie diet and increased physical activity, can reduce excess weight in patients with obesity. MiRNAs are small non-coding single stranded RNAs that regulate gene expression post-transcriptionally by inhibiting their mRNA target translation into proteins. MiRNAs can be secreted in the blood stream and affect the molecular pathways of d...

ob0003cd1.2 | Case Discussions 1 | OU2021

Liraglutide 3.0 mg within a NHS Tier-3/4 weight management service results in similar weight loss compared to regulatory trials – The LIPOSAX first UK real-world evidence study

Dimitriadis Georgios K , Spencer Lewis , Dimitri Federica , Bate Danielle , Leca Bianca M , Duggirala Aparna , Davasgaium Allan , Aylwin Simon JB , Miras Alexander D , Vincent Royce P , le Roux Carel W , Christian Mark , Randeva Harpal S , Tripathi Gyanendra

Liraglutide 3 mg daily is an approved, prescription injectable GLP-1 receptor agonist, which can reduce weight in patients with obesity, with or without obesity complications. We conducted a 24-week, open-label real-world study involving 62 participants with a BMI >30 kg/m2 or >27 kg/m2 if they had co-existing dyslipidaemia or hypertension. No patients had type 2 diabetes. Patients received once-daily subcutaneous liraglutide 3.0 mg, alongside NHS...